Search Medical Condition
Please enter condition
Please choose location from dropdown

Asahikawa, Japan Clinical Trials

A listing of Asahikawa, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (29) clinical trials

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

0.0 miles

Learn More »

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-nave subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Phase

0.0 miles

Learn More »

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

The objectives of this study are: to evaluate the safety, tolerability, and systemic pharmacokinetics (PK) of different doses of inhaled ALX-0171 in Japanese infants and young children hospitalized for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI). to evaluate the antiviral effect, clinical activity, immunogenicity, and pharmacodynamics (PD) of ...

Phase

0.0 miles

Learn More »

To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.

Phase

0.0 miles

Learn More »

A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis ( SELECT Axis 1 )

This is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS).

Phase

0.0 miles

Learn More »

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens ...

Phase

0.53 miles

Learn More »

Maintenance Treatment of Renal Anemia in Dialysis Subjects

The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).

Phase

1.07 miles

Learn More »

A Study to Assess Efficacy Safety Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).

The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Phase

2.12 miles

Learn More »

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

2.12 miles

Learn More »